Hybrid therapy for chronic critical limb ischemia-combination of gene transfer via Sendai virus and endothelial cell plantation.

我们的最终目标是通过仙台病毒将基因转移与骨髓或外周血细胞移植相结合的杂交疗法能够完成。在这项初步研究中，我们研究了西洛他唑是否能改善小鼠缺血后肢的血流，如果是的话，我们还探讨了血管生成的机制。根据我们的结果，西洛他唑可在小鼠后肢缺血模型中诱导血管生成。这种血管生成可能是由于一氧化氮生成的增加。我们的最终目标是，在不久的将来，可以建立通过塞代病毒进行基因转移和细胞移植相结合的杂交疗法。

Our final goal is that hybrid therapy combined gene transfer via Sendai virus with bone marrow or peripheral blood cell transplantation can be completed. In this preliminary study, we investigated whether cilostazol induces improvement of blood flow in the ischemic hindlimb of mouse, and if so, examined the mechanisms of angiogenesis. Based on our results, cilostazol caused angiogenesis in ischemic hindlimb model of mouse. This angiogenesis may be due to the enhancement of nitric oxide production. Our final destination is that hybrid therapy with a combination between gene transfer via Sedai virus and cell transplantation can be established in near future.